|Reason for decision
|Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- If you have any queries please email firstname.lastname@example.org
|25 April 2023
|As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Acalabrutinib with bendamustine and rituximab within its marketing authorisation for untreated mantle cell lymphoma [ID6155]. Please note that following on from advice received from the company this appraisal will be rescheduled to align with latest regulatory expectations.
|11 July 2022
|Awaiting development. Status change linked to Topic Selection Decision being set to Selected
For further information on our processes and methods, please see our CHTE processes and methods manual